<DOC>
	<DOCNO>NCT00176787</DOCNO>
	<brief_summary>This study use experimental combination treatment drug Capecitabine radiation therapy prior operation removal patient 's tumor . The drug Capecitabine oral form drug call 5-FU widely use treat rectal cancer . This phase II clinical trial , mean physician study reaction patient 's body tumor treatment Capecitabine radiation therapy . The purpose study see tumor responds treatment determine long response last . The study also see kind side effect experimental treatment cause see often side effect occur . Preliminary human study use Capecitabine radiation therapy produce encouraging result acceptable side effect .</brief_summary>
	<brief_title>Radiation Therapy With Capecitabine Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Eligibility Criteria 1 . Histologic confirmation adenocarcinoma rectum . 2 . The lesion must locate rectum . For purpose study , lesion must within 12 cm anus measure sigmoidoscopy . 3 . Patients must indication locally advanced lesion define study tumor bowel wall ( &gt; T3 ) involve regional lymph node ( &gt; N1 ) . Clinical stage determination may make physical examination ( T4 lesion ) , endoscopic ultrasound CT scan pelvis . 4 . Patients metastatic disease eligible provide operative intervention primary site anticipate . 5 . Patients must adequate organ function define pretreatment leukocyte count &gt; 3,000/ul , platelet count &gt; 100,000/ul , serum creatinine &lt; 2.0 mg/dl , serum bilirubin &lt; 2 mg/dl . Note : Capecitabine contraindicate patient severe renal impairment ( creatinine clearance &lt; 30 ml/min ) . In patient calculated creatinine clearance 3050 ml/min capecitabine begin ( ) 1 level dose reduction ( see section 6.3 ) 6 . Patients must least 18 year age Zubrod performance status &lt; 2 ( see appendix 1 . ) 7 . Patients must inform investigational nature study provide write informed consent accordance institutional federal guideline prior initiation therapy . 1 . Patients may receive previous pelvic irradiation indication , previous chemotherapy cancer therapy within precede 6 month . 2 . Patients must serious medical psychiatric illness would limit ability patient receive protocol therapy provide inform consent . 3 . Pregnant lactate woman may participate . Women/men reproductive potential must agree use effective contraceptive method . 4 . Patients lack physical integrity upper gastrointestinal tract , inability swallow tablet malabsorption syndrome eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>